Tetraphase Pharmaceuticals, Inc
16
1
1
15
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 16 trials
100.0%
+13.5% vs industry average
25%
4 trials in Phase 3/4
33%
5 of 15 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (16)
A Study to Evaluate the Safety and Tolerability of Eravacycline in Pediatric Patients Aged 8 to 17 With Complicated Intra-abdominal Infections (cIAI)
Role: lead
Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections
Role: lead
Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Complicated Intra-abdominal Infections
Role: lead
Efficacy and Safety Study of Eravacycline Compared With Meropenem in Complicated Intra-abdominal Infections
Role: lead
Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections
Role: lead
Study to Compare TP-434 and Ertapenem in Community-acquired Complicated Intra-abdominal Infections
Role: lead
A Thorough QT/QTc Study to Evaluate the Effects of an Intravenous Infusion of Eravacycline (TP-434) on Cardiac Repolarization
Role: lead
Phase 1, Safety and Bronchopulmonary PK Study in Healthy Volunteers
Role: lead
A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With End Stage Renal Disease and Healthy Subjects
Role: lead
A Phase 1 TP-271 Oral PK Multiple Ascending Dose Study
Role: lead
A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With Impaired Hepatic Function and Healthy Subjects
Role: lead
Safety and Pharmacokinetic (PK) Study to Assess Bronchopulmonary Disposition of IV Eravacycline (TP-434) in Healthy Men and Women
Role: lead
A Phase 1 Safety and PK Study of IV TP-271
Role: lead
A Phase 1 Study to Assess the Safety, Tolerability and PK of IV TP-271
Role: lead
A Phase 1 TP-271 Oral PK Single Ascending Dose Study
Role: lead
A Safety and PK Study of IV Eravacycline
Role: lead
All 16 trials loaded